Our Story
TrovaNOW is dedicated to increasing the 5-year survival rate of pancreatic cancer from 12.8% to 50% within the next decade. By supporting the Pancreatic Cancer Early Detection (PRECEDE) Consortium, TrovaNOW collaborates with over 35 leading academic medical centers worldwide to enhance early detection, screening, and risk modeling for this deadly disease.